Main Line Health
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Main Line Health sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Main Line Health: 3 sponsored US clinical trials, 1 recruiting.
Main Line Health sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pacemaker-Induced Cardiomyopathy, with 1 trials.
Upper-quartile sponsor footprint
Main Line Health sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
NCT06439524
Comparison of Left Bundle Branch Area Versus Right Ventricular Septal Pacing in Patients With High-degree Conduction Disease After Transcatheter Aortic Valve Replacement (Left Bundle BRAVE)
NCT05541679
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy
NCT01727531
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Where Main Line Health enrollment is open (later-stage tilt)
1 recruiting of 3 indexed (33% open); 1 completed (33%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Pacemaker-Induced Cardiomyopathy (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Main Line Health: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Main Line Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Main Line Health page
3 registered trials is a research-attention snapshot, not an endorsement of Main Line Health or any single study.
- 1 of Main Line Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pacemaker-Induced Cardiomyopathy is the condition Main Line Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pacemaker-Induced Cardiomyopathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Main Line Health pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.